JY
SYRS

Jeff Yass’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Jeff Yass’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13,900
Closed -$3.2K – 13724
2024
Q4 		$3.2K Sell
13,900
-41,300
-75% -$49.6K ﹤0.01% 12014
2024
Q3 		$119K Buy
55,200
+44,400
+411% +$159K ﹤0.01% 10931
2024
Q2 		$55.7K Sell
10,800
-2,000
-16% -$10.5K ﹤0.01% 11361
2024
Q1 		$68.5K Sell
12,800
-64,500
-83% -$446K ﹤0.01% 11424
2023
Q4 		$602K Sell
77,300
-2,600
-3% -$8.9K ﹤0.01% 8205
2023
Q3 		$316K Sell
79,900
-700
-0.9% -$2.62K ﹤0.01% 9235
2023
Q2 		$254K Buy
80,600
+600
+0.8% +$1.93K ﹤0.01% 9780
2023
Q1 		$214K Sell
80,000
-23,200
-22% -$89.9K ﹤0.01% 10459
2022
Q4 		$370K Buy
103,200
+1,200
+1% +$5.21K ﹤0.01% 8597
2022
Q3 		$657K Buy
+102,000
New +$829K ﹤0.01% 7730
2021
Q3 		– Sell
-3,510
Closed -$191K – 13743
2021
Q2 		$191K Sell
3,510
-1,400
-29% -$82.9K ﹤0.01% 11646
2021
Q1 		$367K Sell
4,910
-3,470
-41% -$360K ﹤0.01% 10181
2020
Q4 		$909K Buy
+8,380
New +$765K ﹤0.01% 6933
2020
Q1 		– Sell
-3,530
Closed -$244K – 11031
2019
Q4 		$244K Sell
3,530
-1,510
-30% -$91.6K ﹤0.01% 8409
2019
Q3 		$523K Buy
+5,040
New +$476K ﹤0.01% 7222
2018
Q4 		– Sell
-2,340
Closed -$279K – 10148
2018
Q3 		$279K Buy
2,340
+1,200
+105% +$139K ﹤0.01% 7622
2018
Q2 		$116K Sell
1,140
-740
-39% -$91.6K ﹤0.01% 8982
2018
Q1 		$244K Buy
+1,880
New +$206K ﹤0.01% 7976

Other funds holding SYRS

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $339M AUM 120.53% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Jeff Yass's SYRS Position: Q3 2024 in Review

Jeff Yass sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2024, closing a stake of 30,005 shares — an estimated $108K sold.

Jeff Yass first reported a position in SYRS in Q4 2018 and held it in 18 quarters. The position peaked at $1.06M in Q4 2020. 65 funds tracked by Wall St. Rank hold SYRS as of Q3 2024.

  • Jeff Yass reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Jeff Yass sold 30,005 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2024, an estimated $108K.
  • Jeff Yass first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 18 quarters.
  • Jeff Yass's Syros Pharmaceuticals, Inc. Common Stock position peaked at $1.06M in Q4 2020.
  • 65 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2024.

Based on Susquehanna International Group's 13F filing for Q3 2024, filed 14 Nov 2024.